Therefore, in this report, we explore the issue of limited elimination of p53wt cancer cells by idasanutlin and provide proofs for the de novo development of TP53-mutated drug-resistant cell populations out of idasanutlin-responsive p53wt U-2 OS cells. The gene discussed is TP53; the disease is cancer.